Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jan;29(1):9–18. doi: 10.1111/j.1365-2125.1990.tb03596.x

Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

R Zini 1, D Morin 1, C Salvadori 1, J P Tillement 1
PMCID: PMC1380055  PMID: 2297464

Abstract

1. The binding of tianeptine to human plasma, isolated plasma proteins, red blood cells and to plasma from patients with cirrhosis or renal failure was studied in vitro by equilibrium dialysis. 2. Tianeptine is highly bound to plasma (95%) at therapeutic concentrations (0.3-1 microM). No saturation of the binding sites was seen. 3. Human serum albumin (HSA) was shown to be mainly responsible for this binding (94%) with a saturable process characterized by one binding site with a moderate affinity (Ka = 4.2 x 10(4) M-1) and a non-saturable process with a low total affinity (nKa = 1.2 x 10(4) M-1). 4. Like many basic and amphoteric drugs, tianeptine showed a saturable binding to alpha 1-acid glycoprotein (AAG) with one site and a moderate affinity (Ka = 3.7 x 10(4) M-1). Its binding to lipoproteins and red blood cells (RBC) was weak and non-saturable. Over the range of therapeutic drug concentrations (0.3-1 microM), the unbound fraction in blood remains constant (4.5%). 5. Interactions were studied using non-esterified fatty acids (NEFA) at pathological concentrations; they altered tianeptine binding to plasma and to isolated HSA. Tianeptine seems to bind to a HSA site different from sites I (warfarin) and II (diazepam), but close to site II. It also shares the only basic-site on AAG. However, at therapeutic drug concentrations (0.3-1 microM), not all of these interactions occur. 6. The binding of tianeptine varied according to HSA, AAG and NEFA concentrations both in patients and healthy subjects. In patients with chronic renal failure having high NEFA concentrations the unbound fraction of tianeptine (fu) increased from 0.045 to 0.153 compared with normal (P less than 0.001). In cirrhotic patients, with relatively low HSA concentrations, the fu of tianeptine increased from 0.045 to 0.088 compared with normal (P less than 0.01). 7. Multiple regression analysis of all of the data indicated that the fu of tianeptine was related significantly to HSA, NEFA and AAG concentrations, with a particularly strong correlation with NEFA concentrations. Therefore, variation of HSA and NEFA concentrations in patients on maintenance therapy may cause an increase of tianeptine fu.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre J., Houin G., Rosenbaum J., Zini R., Dhumeaux D., Tillement J. P. Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol. 1984 Oct;18(4):652–653. doi: 10.1111/j.1365-2125.1984.tb02525.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baruzzi A., Contin M., Perucca E., Albani F., Riva R. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration. Eur J Clin Pharmacol. 1986;31(1):85–89. doi: 10.1007/BF00870992. [DOI] [PubMed] [Google Scholar]
  3. Birkett D. J., Myers S. P., Sudlow G. The fatty acid content and drug binding characteristics of commercial albumin preparations. Clin Chim Acta. 1978 May 2;85(3):253–258. doi: 10.1016/0009-8981(78)90302-9. [DOI] [PubMed] [Google Scholar]
  4. Bowmer C. J., Lindup W. E. Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharmacol. 1982 Feb 1;31(3):319–323. doi: 10.1016/0006-2952(82)90177-0. [DOI] [PubMed] [Google Scholar]
  5. Braithwaite R. A. Plasma-protein binding of tricyclic antidepressants. Postgrad Med J. 1980;56 (Suppl 1):107–111. [PubMed] [Google Scholar]
  6. Brodersen R., Honoré B., Larsen F. G. Serum albumin--a non-saturable carrier. Acta Pharmacol Toxicol (Copenh) 1984 Feb;54(2):129–133. doi: 10.1111/j.1600-0773.1984.tb01906.x. [DOI] [PubMed] [Google Scholar]
  7. Brodersen R., Honoré B., Pedersen A. O., Klotz I. M. Binding constants for ligand-carrier complexes. Trends Pharmacol Sci. 1988 Jul;9(7):252–257. doi: 10.1016/0165-6147(88)90155-1. [DOI] [PubMed] [Google Scholar]
  8. Brown J. E., Kitchell B. B., Bjornsson T. D., Shand D. G. The artifactual nature of heparin-induced drug protein-binding alterations. Clin Pharmacol Ther. 1981 Nov;30(5):636–643. doi: 10.1038/clpt.1981.215. [DOI] [PubMed] [Google Scholar]
  9. David B. M., Tjokrosetio R., Ilett K. F. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration. Ther Drug Monit. 1983;5(1):81–86. doi: 10.1097/00007691-198303000-00007. [DOI] [PubMed] [Google Scholar]
  10. Defrance R., Marey C., Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol. 1988;11 (Suppl 2):S74–S82. [PubMed] [Google Scholar]
  11. Essassi D., Zini R., Hamberger C., Urien S., Rougeot C., Uzan A., Tillement J. P. Binding in vitro of pipequaline (45319 RP) onto plasma proteins and blood cells in man. Biochem Pharmacol. 1987 Oct 15;36(20):3501–3507. doi: 10.1016/0006-2952(87)90332-7. [DOI] [PubMed] [Google Scholar]
  12. Glasson S., Zini R., Tillement J. P. Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins. Biochem Pharmacol. 1982 Mar 1;31(5):831–835. doi: 10.1016/0006-2952(82)90470-1. [DOI] [PubMed] [Google Scholar]
  13. Glasson S., Zini R., d'Athis P., Tillement J. P., Boissier J. R. The distribution of bound propranolol between the different human serum proteins. Mol Pharmacol. 1980 Mar;17(2):187–191. [PubMed] [Google Scholar]
  14. Hamberger C., Barre J., Zini R., Taiclet A., Houin G., Tillement J. P. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res. 1986;6(6):441–449. [PubMed] [Google Scholar]
  15. Hiramatsu S., Kojima J., Okada T. T., Inai S., Ohmori K. The serum protein profile in chronic hepatitis, cirrhosis and liver cancer. Acta Hepatogastroenterol (Stuttg) 1976 Jun;23(3):177–182. [PubMed] [Google Scholar]
  16. Honoré B., Brodersen R. Albumin binding of anti-inflammatory drugs. Utility of a site-oriented versus a stoichiometric analysis. Mol Pharmacol. 1984 Jan;25(1):137–150. [PubMed] [Google Scholar]
  17. Horiuchi T., Johno I., Hasegawa T., Kitazawa S., Goto M., Hata T. Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients. Eur J Clin Pharmacol. 1989;36(2):175–180. doi: 10.1007/BF00609191. [DOI] [PubMed] [Google Scholar]
  18. Iwatsuru M., Nishigori H., Maruyama K. The classification of drugs on the basis of the drug-binding site on human serum albumin. Chem Pharm Bull (Tokyo) 1982 Dec;30(12):4489–4493. doi: 10.1248/cpb.30.4489. [DOI] [PubMed] [Google Scholar]
  19. Kato G., Weitsch A. F. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol. 1988;11 (Suppl 2):S43–S50. [PubMed] [Google Scholar]
  20. Kessler K. M., Leech R. C., Spann J. F. Blood collection techniques, heparin and quinidine protein binding. Clin Pharmacol Ther. 1979 Feb;25(2):204–210. doi: 10.1002/cpt1979252204. [DOI] [PubMed] [Google Scholar]
  21. King T. P. On the location of the primary organic ligand binding site of bovine plasma albumin. Ann N Y Acad Sci. 1973 Nov 26;226:94–100. doi: 10.1111/j.1749-6632.1973.tb20472.x. [DOI] [PubMed] [Google Scholar]
  22. Klotz U., Antonin K. H., Bieck P. R. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther. 1976 Oct;199(1):67–73. [PubMed] [Google Scholar]
  23. Kragh-Hansen U. Relations between high-affinity binding sites of markers for binding regions on human serum albumin. Biochem J. 1985 Feb 1;225(3):629–638. doi: 10.1042/bj2250629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  25. Lôo H., Hantzberg P., Defrance R., Kamoun A., Deniker P. Traitement par la tianeptine des syndromes dépressifs des toxicomanes sevrés. Appréciation de l'efficacité et recherche de dépendance. Encephale. 1987 Sep-Oct;13(5):295–299. [PubMed] [Google Scholar]
  26. Lôo H., Malka R., Defrance R., Barrucand D., Benard J. Y., Niox-Rivière H., Raab A., Sarda A., Vachonfrance G., Kamoun A. Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology. 1988;19(2):79–85. doi: 10.1159/000118439. [DOI] [PubMed] [Google Scholar]
  27. Mennini T., Mocaer E., Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1987 Nov;336(5):478–482. doi: 10.1007/BF00169302. [DOI] [PubMed] [Google Scholar]
  28. Morin D., Zini R., Ledewyn S., Colonna J. P., Czajka M., Tillement J. P. Binedaline binding to plasma proteins and red blood cells in humans. J Pharm Sci. 1985 Jul;74(7):727–730. doi: 10.1002/jps.2600740706. [DOI] [PubMed] [Google Scholar]
  29. Müller W. E., Stillbauer A. E. Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid). Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):170–173. doi: 10.1007/BF00512392. [DOI] [PubMed] [Google Scholar]
  30. Pedersen L. E., Bonde J., Graudal N. A., Backer N. V., Hansen J. E., Kampmann J. P. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Br J Clin Pharmacol. 1987 Jan;23(1):41–46. doi: 10.1111/j.1365-2125.1987.tb03007.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Peters T., Jr Serum albumin: recent progress in the understanding of its structure and biosynthesis. Clin Chem. 1977 Jan;23(1):5–12. [PubMed] [Google Scholar]
  32. Piafsky K. M. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980 May-Jun;5(3):246–262. doi: 10.2165/00003088-198005030-00004. [DOI] [PubMed] [Google Scholar]
  33. Pritchard J. F., O'Neill P. J., Affrime M. B., Lowenthal D. T. Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clin Pharmacol Ther. 1983 Nov;34(5):681–688. doi: 10.1038/clpt.1983.232. [DOI] [PubMed] [Google Scholar]
  34. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  35. Routledge P. A. The plasma protein binding of basic drugs. Br J Clin Pharmacol. 1986 Nov;22(5):499–506. doi: 10.1111/j.1365-2125.1986.tb02927.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Royer R. J., Albin H., Barrucand D., Salvadori-Failler C., Kamoun A. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clin Neuropharmacol. 1988;11 (Suppl 2):S90–S96. [PubMed] [Google Scholar]
  37. Royer R. J., Royer-Morrot M. J., Paille F., Barrucand D., Schmitt J., Defrance R., Salvadori C. Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis. Clin Pharmacokinet. 1989 Mar;16(3):186–191. doi: 10.2165/00003088-198916030-00005. [DOI] [PubMed] [Google Scholar]
  38. Rudman D., Bixler T. J., 2nd, Del Rio A. E. Effect of free fatty acids on binding of drugs by bovine serum albumin, by human serum albumin and by rabbit serum. J Pharmacol Exp Ther. 1971 Feb;176(2):261–272. [PubMed] [Google Scholar]
  39. Sjöholm I., Ekman B., Kober A., Ljungstedt-Påhlman I., Seiving B., Sjödin T. Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol. 1979 Nov;16(3):767–777. [PubMed] [Google Scholar]
  40. Sudlow G., Birkett D. J., Wade D. N. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976 Nov;12(6):1052–1061. [PubMed] [Google Scholar]
  41. Thiessen J. J., Sellers E. M., Denbeigh P., Dolman L. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol. 1976 Jul;16(7):345–351. doi: 10.1002/j.1552-4604.1976.tb01531.x. [DOI] [PubMed] [Google Scholar]
  42. Tillement J. P., Lhoste F., Giudicelli J. F. Diseases and drug protein binding. Clin Pharmacokinet. 1978 Mar-Apr;3(2):144–154. doi: 10.2165/00003088-197803020-00004. [DOI] [PubMed] [Google Scholar]
  43. Verbeeck R. K., Cardinal J. A., Wallace S. M. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol. 1984;27(1):91–97. [PubMed] [Google Scholar]
  44. Zini R., Barre J., Defer G., Jeanniot J. P., Houin G., Tillement J. P. Protein binding of propisomide. J Pharm Sci. 1985 May;74(5):530–533. doi: 10.1002/jps.2600740507. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES